August 15, 2025International Journal of ObesityOpen Access

Gastrointestinal adverse events associated with GLP-1 RA in non-diabetic patients with overweight or obesity: a systematic review and network meta-analysis

View Full Paper

Ask AI

Bookmark

Authors

AIAbdulrahman IsmaielIuliu Hațieganu University of Medicine and Pharmacy GSGiuseppe Guido Maria ScarlataMagna Graecia University IBIrina BoitosIuliu Hațieganu University of Medicine and Pharmacy

Discussion

Member takes

Implication

Systematic review reveals increased gastrointestinal adverse events in non-diabetic individuals with obesity, highlighting the need for balanced treatment decisions.

Key Points

GLP-1 RAs are linked to several gastrointestinal adverse effects in non-diabetic patients with obesity.
Among 33,354 evaluated individuals, significant nausea risk was identified, particularly with orforglipron.
This systematic review and network meta-analysis synthesize evidence from 39 articles assessing these adverse events.
Understanding risk differences in GLP-1 RAs helps clinicians balance benefits with potential side effects.

Cite This Study

Ismaiel et al. (2025) studied this question.

synapsesocial.com/papers/68a365600a429f797332b3fa https://doi.org/10.1038/s41366-025-01859-6

View Full Paper

Ask AI

Bookmark

Implication

Systematic review reveals increased gastrointestinal adverse events in non-diabetic individuals with obesity, highlighting the need for balanced treatment decisions.

Gastrointestinal adverse events associated with GLP-1 RA in non-diabetic patients with overweight or obesity: a systematic review and network meta-analysis

Discussion

Member takes

Implication

Key Points

Cite This Study

Gastrointestinal adverse events associated with GLP-1 RA in non-diabetic patients with overweight or obesity: a systematic review and network meta-analysis

Discussion

Member takes

Implication

Key Points

Cite This Study

Also Consider

Also Consider